Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 6/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 4/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229204 | 0.93 | MAPT (0.41) | MAPTFDPSFAAHCES1CES2 | |
| SCHEMBL10689014 | 0.91 | MAPT (0.44) | MAPTFDPSFAAHCES1CES2 | |
| SCHEMBL4644188 | 0.91 | MAPT (0.44) | MAPTFDPSFAAHCES1CES2 | |
| SCHEMBL1534090 | 0.86 | LMNA (0.30) | — | |
| SCHEMBL28173890 | 0.83 | MAPT (0.31) | ALDH1A1MAPTCA2CA1FDPS | |
| SCHEMBL3367883 | 0.78 | MAPT (0.44) | MAPTCA2CA1FAAHMAPK1 | |
| SCHEMBL5198247 | 0.78 | MAPT (0.31) | ALDH1A1MAPTCA2CA1FDPS | |
| SCHEMBL3070772 | 0.77 | MAPT (0.31) | ALDH1A1MAPT | |
| SCHEMBL27741759 | 0.77 | CES2 (0.46) | MAPTCA2CA1FAAHMAPK1 | |
| SCHEMBL23825068 | 0.76 | FDPS (0.36) | ALDH1A1MAPTCA2CA1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849068-B | Method for preparing polyhedral oligomeric silsesquioxanes | 株式会社LG化学 | 2020-09-11 | — | — | CN | claimed |
| US-10683313-B2 | Polyhedral oligomeric silsesquioxane and preparation method thereof | LG CHEM, LTD. (KR) | 2020-06-16 | — | — | US | claimed |
| US-10501583-B2 | Method for preparing polyhedral oligomeric silsesquioxane | LG CHEM, LTD. (KR) | 2019-12-10 | — | — | US | claimed |
| US-20190023728-A1 | POLYHEDRAL OLIGOMERIC SILSESQUIOXANE AND PREPARATION METHOD THEREOF | LG CHEM, LTD. (KR) | 2019-01-24 | — | — | US | claimed |
| US-20180201734-A1 | METHOD FOR PREPARING POLYHEDRAL OLIGOMERIC SILSESQUIOXANE | LG CHEM, LTD. (KR) | 2018-07-19 | — | — | US | claimed |
| CN-107209146-B | Electrochemical gas sensor and electrolyte for electrochemical gas sensor | 德尔格安全股份两合公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-108473515-B | Polyhedral oligomeric silsesquioxane and preparation method thereof | 株式会社LG化学 | 2021-01-12 | — | — | CN | disclosed |
| US-10835895-B2 | Compound and synthesis method therefor | THE UNIVERSITY OF TOKYO (JP) | 2020-11-17 | — | — | US | disclosed |
| CN-107849068-B | Method for preparing polyhedral oligomeric silsesquioxanes | 株式会社LG化学 | 2020-09-11 | — | — | CN | disclosed |
| US-10683313-B2 | Polyhedral oligomeric silsesquioxane and preparation method thereof | LG CHEM, LTD. (KR) | 2020-06-16 | — | — | US | disclosed |
| US-10501583-B2 | Method for preparing polyhedral oligomeric silsesquioxane | LG CHEM, LTD. (KR) | 2019-12-10 | — | — | US | disclosed |
| US-20190111418-A1 | COMPOUND AND SYNTHESIS METHOD THEREFOR | THE UNIVERSITY OF TOKYO (JP) | 2019-04-18 | — | — | US | disclosed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-5698636-A | HAVING MALEIMIDE DERIVATIVE, ALPHA-METHYLSTYRENE, AND N,N-DIMETHYLACRYLAMIDE UNITS | TOMEY TECHNOLOGY CORPORATION (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0790520-A1 | MATERIAL OF OPHTHALMIC LENSES AND PROCESS FOR THE PRODUCTION THEREOF | TOMEY TECHNOLOGY CORPORATION (JP) | 1997-08-20 | — | — | EP | disclosed |
| US-4525563-A | Oxygen permeable soft contact lens composition | TOYO CONTACT LENS CO. (JP) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009398-A1 | p27 Protein Inducer | CDKN1A, CDK2, SKP2 | ALDH1A1 1983/4885MAPT 4152/4885CA2 291/4885 |
| US-10835895-B2 | Compound and synthesis method therefor | GOT1, GOT2, SLC39A11 | ALDH1A1 73/4885MAPT 2610/4885CA2 1663/4885 |
| US-20190111418-A1 | COMPOUND AND SYNTHESIS METHOD THEREFOR | GOT1, GOT2, SLC39A11 | ALDH1A1 90/4885MAPT 2907/4885CA2 1602/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | ALDH1A1 452/4885MAPT 4754/4885CA2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.